As states continue to grapple with prescription drug costs, “cost-effectiveness” reviews are being considered as one method to determine treatment access and reimbursement decisions. Pioneer Institute explores the potential impacts that ICER and one-size-fits-all methods to healthcare value assessment could have for certain patient populations and medical innovation itself.
